Randomised Total Knee Arthroplasty With Attune S+ or NexGen CR

NCT ID: NCT05464641

Last Updated: 2025-04-25

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

150 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-01-01

Study Completion Date

2024-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The primary purpose of this study is to evaluate the clinical performance of the Attune S+ knee primarily based on evaluation with use of Oxford Knee Score. The NexGen TKR will be used as reference standard. The second aim is to study component migration with model-based RSA in a subgroup of patients with model-based RSA and to compare these measurements with migration measurements with use of CT-based migration measurements. The investigators hypothesis is that the results two years after insertion of these two TKR designs will be about equal.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The Attune knee was launched in 2012. From a clinical point of view some studies indicate superior clinical performance of the Attune when compared to the PFC. Carey and Harty operated 21 patients with both the Attune and the POFC Sigma knees. At six months' clinical scores were superior for the Attune side as was range of movement. Ranawat 2017, matched 100 Attune to 100 PFC Sigma knee operations based on age, gender, side and BMI but found no difference in clinical results after 2 years.

Bonutti reviewed three hospital databases and described 2 cases with loosening of the tibial component due to debonding between the cement and the implant, but the total material from which these cases were collected was not known or mentioned. Turgeon studied the fixation of 30 consecutive cases operated with the Attune knee and observed a mean maximum total point motion of 0.08 mm between 12 and 24 months, which suggests an acceptably low risk of medium to long-term failure due to aseptic loosening. Staats evaluated incidence of radiolucent lines in 276 Attune and 253 PFC Sigma TKRs up to one year after operation and observed a higher incidence in the former group.

In the last report from NJR from 2020, the 5-year revision rate of the Attune FB knee is 2.71 (2.32-3.17), which is slightly above average (2.23, 2.20-2.26). In the Australian registry from 2020 the corresponding cumulative percent revision rate of cemented Attune CR is 3.0 % (2.7 - 3.5) at 5 years.

In an ongoing study the investigators have randomized 95 knees with knee osteoarthritis to either become operated with an Attune knee (n=49) or a PFC knee (n=46). Preliminary results at one year show almost equal results when evaluated in terms of Oxford Knee or Forgotten Joint Scores.

NexGen metal-backed tibia is the most commonly used total knee prosthesis in Sweden. Its revision rate is one of the lowest observed in the Swedish Register. The 5 years survival in the report from NJR from 2020 is 2.1% (2.05 - 2.21) and in the report from the Australian register it is about equal (2.0; 1.9 - 2.2). The Australian Register also present survival at 19 years amounting to 5.7% (4.7 - 6.9) being the lowest cumulative revision of those specific cemented TKRs accounted for with that long follow up.

In 2017 DePuy launched the Attune S+ tibial components in order to address the potential problem of loosening between the cement and the tibial tray. If and if so, to what extent this modification will change the clinical outcome of TKRs operated with this implant is not known. Based on the high survival rate of the in Sweden frequently used NexGen TKR a comparative study between the Attune S+ and the NexGen TKRs would provide an important benchmark for the performance of the Attune S+ knee.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Arthroplasty, Replacement, Knee

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

preoperative and 2 year postoperative
Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

SINGLE

Participants
preoperative and 2 year postoperative

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

preoperative

preoperative The Oxford Knee Score (OKS) is a 12-item patient-reported PRO, low score worse.

Group Type ACTIVE_COMPARATOR

Oxford knee score

Intervention Type OTHER

The Oxford Knee Score (OKS) is a 12-item patient-reported PRO, low score worse

postoperative

postoperative The Oxford Knee Score (OKS) is a 12-item patient-reported PRO, low score worse.

Group Type ACTIVE_COMPARATOR

Oxford knee score

Intervention Type OTHER

The Oxford Knee Score (OKS) is a 12-item patient-reported PRO, low score worse

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Oxford knee score

The Oxford Knee Score (OKS) is a 12-item patient-reported PRO, low score worse

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Medial or lateral primary OA Ahlbäck Grade 2-4
* Varus or valgus deformity ≤10 degrees, extension defect ≤10 degrees
* Age 40-75 years
* BMI \<35
* ASA 1-3.
* Coming from independent living in own home
* Written informed consent.

Exclusion Criteria

* Cortisone treatment during the last 6 months before operation
* Neurological diseases with symptoms, stroke with sequel
* Endocrine diseases with symptoms
* OA secondary to trauma, infection, inflammatory disease or congenital and acquired deformities
* BMI \>=35
Minimum Eligible Age

40 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Göteborg University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Roland Zügner, PhD

Role: PRINCIPAL_INVESTIGATOR

Göteborg University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Roland Zügner

Gothenburg, , Sweden

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Sweden

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

Attune S+ or NexGen CR

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Survivorship of Attune Primary Total Knee Prosthesis
NCT01754363 ACTIVE_NOT_RECRUITING NA
China ATTUNE® Study
NCT03542045 COMPLETED
Anatomic Congruent Prosthetic Knee Design
NCT03633201 ACTIVE_NOT_RECRUITING NA
TC-A Registration Study
NCT02139345 COMPLETED NA